BioNTech Shares Under Pressure as Key Investor Exits

The German biotech firm BioNTech finds itself navigating turbulent waters following a significant divestment by its longtime collaborator. In a decisive overnight move, Pfizer sold its entire remaining stake of 4.55 million American Depositary Receipts (ADRs), sending a stark signal to the market and contributing to a sharp pre-market decline in the share price.

Pfizer’s decision to liquidate its entire position marks a pivotal moment for BioNTech. The shares were offloaded via a block trade at prices ranging from $108 to $111.70 per ADR. This is more than a simple portfolio rebalancing; it is widely interpreted as a clear vote of no confidence from a former ally in the company’s near-term Read more...